Asymchem Labs reports Q3 2025 revenue growth, boosted by new orders

Asymchem Laboratories (Tianjin) Co., Ltd. reported total operating revenue of 4.63 billion yuan for the first three quarters of 2025, an 11.82% increase year-on-year. Net profit attributable to shareholders of listed companies grew by 12.66% to 800.25 million yuan, while net profit excluding non-recurring gains and losses rose by 9.74% to 728.02 million yuan. Basic and diluted earnings per share for the period were 2.18 yuan, up 8.46% from the previous year.

The company's gross profit margin for the first three quarters stood at 42.44%, with the small molecule business maintaining its gross profit margin at 46.99%. Emerging businesses saw a significant increase in gross profit margin by 10.57 percentage points to 30.55%, primarily driven by increased delivery volumes and improved capacity utilization.

New orders, particularly in the peptide, oligonucleotide, and ADC segments, achieved double-digit growth. The company anticipates full-year operating revenue to increase by 13-15%, with fourth-quarter deliveries expected to be significantly higher than the third quarter.